Search

Your search keyword '"Domingo Pere"' showing total 1,834 results
Start Over Author "Domingo Pere"
1,834 results on '"Domingo Pere"'

201. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period

Author

Kowalska, Justyna D., primary, Pelchen-Matthews, Annegret, additional, Ryom, Lene, additional, Losso, Marcelo H., additional, Trofimova, Tatiana, additional, Mitsura, Viktar M., additional, Khromova, Irina, additional, Paduta, Dzmitry, additional, Stephan, Christoph, additional, Domingo, Pere, additional, Bakowska, Elzbieta, additional, Monforte, Antonella d’Arminio, additional, Oestergaard, Lars, additional, Jablonowska, Elzbieta, additional, Kuznetsova, Anastasiia, additional, Moreno, Santiago, additional, Vasylyev, Marta, additional, Pradier, Christian, additional, Battegay, Manuel, additional, Vandekerckhove, Linos, additional, Castagna, Antonella, additional, Raben, Dorthe, additional, and Mocroft, Amanda, additional

Published
2021
Full Text
View/download PDF

202. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

Author

Corominas, Hèctor, primary, Castellví, Ivan, additional, Diaz-Torné, César, additional, Matas, Laia, additional, de la Rosa, David, additional, Mangues, Maria Antònia, additional, Moya, Patricia, additional, Pomar, Virginia, additional, Benito, Natividad, additional, Moga, Ester, additional, Sosa, Nerea Hernandez-de, additional, Casademont, Jordi, additional, and Domingo, Pere, additional

Published
2021
Full Text
View/download PDF

203. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.

Author

Nomah, Daniel K, Reyes-Urueña, Juliana, Díaz, Yesika, Moreno, Sergio, Aceiton, Jordi, Bruguera, Andreu, Vivanco-Hidalgo, Rosa M, Casabona, Jordi, Domingo, Pere, Navarro, Jordi, Imaz, Arkaitz, Deig, Elisabet, Navarro, Gemma, Llibre, Josep M, Miro, Jose M, group, PISCIS study, and PISCIS study group

Abstract

Background: Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.Objectives: We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH).Methods: We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes.Results: After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC.Conclusions: TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

204. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.

Author

Mocroft, Amanda, Miro, Jose M., Wandeler, Gilles, Llibre, Josep M., Boyd, Anders, van Bremen, Kathrin, Beniowski, Marek, Mikhalik, Julia, Cavassini, Matthias, Maltez, Fernando, Duvivier, Claudine, Uberti Foppa, Caterina, Knysz, Brygida, Bakowska, Elzbieta, Kuzovatova, Elena, Domingo, Pere, Zagalo, Alexandra, Viard, Jean‐Paul, Degen, Olaf, and Milinkovic, Ana

Subjects
HEPATITIS B, HIV-positive persons, VIRAL antigens, RESEARCH, CONFIDENCE intervals, DNA, LUNG tumors, MATHEMATICAL variables, ANAL tumors, TUMORS, ODDS ratio, ANTIGENS
Abstract

Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non‐liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person‐years of follow‐up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV‐positive versus HBV‐negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV‐negative individuals, HBsAg‐positive/HBV‐DNA‐positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg‐positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV‐positive subjects with chronic HBV infection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

205. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial

Author

Grau-Pujol, Berta, primary, Camprubí, Daniel, additional, Marti-Soler, Helena, additional, Fernández-Pardos, Marc, additional, Carreras-Abad, Clara, additional, Andrés, Maria Velasco de, additional, Ferrer, Elisabet, additional, Muelas-Fernandez, Magdalena, additional, Jullien, Sophie, additional, Barilaro, Giuseppe, additional, Ajanovic, Sara, additional, Vera, Isabel, additional, Moreno, Laura, additional, Gonzalez-Redondo, Eva, additional, Cortes-Serra, Núria, additional, Roldán, Montserrat, additional, Arcos, Ana Artes de, additional, Mur, Isabel, additional, Domingo, Pere, additional, Garcia, Felipe, additional, Guinovart, Caterina, additional, and Muñoz, Jose, additional

Published
2021
Full Text
View/download PDF

206. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV

Author

Teira, Ramón, primary, Diaz-Cuervo, Helena, additional, Aragão, Filipa, additional, Marguet, Sophie, additional, de la Fuente, Belén, additional, Muñoz, Maria Jose, additional, Abdulghani, Nadia, additional, Ribera, Esteban, additional, Domingo, Pere, additional, Deig, Elisabeth, additional, Peraire, Joaquim, additional, Roca, Bernardino, additional, Montero, Marta, additional, Galindo, Maria José, additional, Romero, Alberto, additional, Espinosa, Nuria, additional, Lozano, Fernando, additional, Merino, María Dolores, additional, Martínez, Elisa, additional, Geijo, Paloma, additional, Estrada, Vicente, additional, García, Josefina, additional, Sepúlveda, M. Antonia, additional, and Berenguer, Juan, additional

Published
2021
Full Text
View/download PDF

209. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a Cohort of Spanish HIV-1-infected subjects

Author

Vilades, Consuelo, Broch, Montserrat, Plana, Montserrat, Domingo, Pere, Alonso-Villaverde, Carlos, and Pedrol, Enric

Subjects
HIV infection -- Genetic aspects, HIV infection -- Natural history, HIV infection -- Risk factors, Genetic variation -- Analysis, Health
Abstract

A study was carried out to determine whether functionally active CCR2 and CCL2 genetic variants influence the risk of infection and disease progression in a cohort of white Spaniards. The distribution of CCL2 alleles showed no significant differences between groups but HIV-1-infected individuals had a significantly higher prevalence of the variant homozygous CCL2 GG genotype as compared to EUs.

Published
2007

210. Linezolid for therapy of Staphylococcus aureus meningitis: a cohort study of 26 patients

Author

Pintado, Vicente, Pazos, Rosario, Jiménez-Mejías, M. E., Rodríguez-Guardado, Azucena, Díaz-Pollán, Beatriz, Cabellos, Carmen, García-Lechuz, Juan Manuel, Lora-Tamayo, Jaime, Domingo, Pere, Múñez, E., Domingo, Diego, González-Romo, Fernando, Lepe, José A., Rodríguez-Lucas, Carlos, Valencia, Eulalia, Pelegrín, Iván, Chaves, F., Pomar, Virginia, Ramos, Antonio, Alarcón, Teresa, Pérez-Cecilia, Elisa, Pintado, Vicente, Pazos, Rosario, Jiménez-Mejías, M. E., Rodríguez-Guardado, Azucena, Díaz-Pollán, Beatriz, Cabellos, Carmen, García-Lechuz, Juan Manuel, Lora-Tamayo, Jaime, Domingo, Pere, Múñez, E., Domingo, Diego, González-Romo, Fernando, Lepe, José A., Rodríguez-Lucas, Carlos, Valencia, Eulalia, Pelegrín, Iván, Chaves, F., Pomar, Virginia, Ramos, Antonio, Alarcón, Teresa, and Pérez-Cecilia, Elisa

Abstract

[Background]: Linezolid has good penetration to the meninges and could be an alternative for treatment of Staphylococcus aureus meningitis. We assessed the efficacy and safety of linezolid therapy for this infection., [Methods]: Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases of S. aureus meningitis diagnosed at 11 university hospitals in Spain (1981-2015)., [Results]: There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistant S. aureus in 15 cases and methicillin-susceptible S. aureus in 11. Linezolid was given as empirical therapy in 10 cases, as directed therapy in 10, and due to failure of vancomycin in 6. Monotherapy was given to 16 (62%) patients. Median duration of linezolid therapy was 17 days (IQR 12-22 days) with a daily dose of 1,200 mg in all cases. The clinical response rate to linezolid was 69% (18/26) and microbiological response was observed in 14 of 15 cases evaluated (93%). Overall 30-day mortality was 23% and was directly associated with infection in most cases. When compared with the patients of the cohort, no significant difference in mortality was observed between patients receiving linezolid or vancomycin for therapy of methicillin-resistant S. aureus meningitis (9% vs. 20%; p = .16) nor between patients receiving linezolid or cloxacillin for therapy of methicillin-susceptible S. aureus meningitis (20% vs 14%; p = .68). Adverse events appeared in 14% (3/22) of patients, but linezolid was discontinued in only one patient., [Conclusions]: Linezolid appears to be effective and safe for therapy of S. aureus meningitis. Our findings showed that linezolid may be considered an adequate alternative to other antimicrobials in meningitis caused by S. aureus.

Published
2020

211. Recomendaciones españolas sobre el uso adecuado de enfuvirtida

Author

Ribera, Esteban, Moreno, Santiago, Viciana, Pompeyo, Echevarría, Santiago, Flores, Juan, Francés, Adela, Luis Gómez-Sirvent, Juan, González, Juan, Hernández-Quero, José, Lozano, Fernando, Mallolas, Josep, Muñoz, Agustín, Ocampo, Antonio, Portilla, Joaquín, Pulido, Federico, Rivero, Antonio, Santos, Jesús, Soriano, Vicente, Antela, Antonio, Arazo, Piedad, Ramón Arribas, José, Cervantes, Manel, and Domingo, Pere

Published
2007
Full Text
View/download PDF

212. Barriers to health care services for migrants living with HIV in Spain

Author

Ndumbi, Patricia, del Romero, J., Pulido, F., Velasco Arribas, M., Dronda, F., Blanco Ramos, J. Ramón, García de Olalla, P., Ocaña, I., Belda-Ibañez, J., del Amo, J., Álvarez-del Arco, D., Gennotte, Anne-Françoise, Barthélemy, C. cile La Morté, Wengenroth, Claudia, Touloumi, Giota, Ilias, Gountas, Loumpiana, Koulai, Olga, Anagnostou, Schüttfort, Gundolf, Wenganroth, Claudia, Barros, Henrique, Meireles, Paula, del Amo, Julia, Álvarez, D. bora, Monge, Susana, Ledergerber, Bruno, Staehelin, Cornelia, Prins, Maria, Bill, Janneke, Zuure, Freke, Prestileo, Tullio, Petrosillo, Nicolla, Burns, Fiona, Fakoya, Ibi, del Romero J, Jorge, Rodríguez, Carmen, Vera, Mar, Río, Isabel, Paredes, Vanessa, Sanz, Nieves, Dronda, Fernando, Arribas, María Velasco, Mateo, María Gracia, Gutiérrez, Mar, Domingo, Pere, Knobel, Hernando, Pellicer, Teresa, Fernández, Emma, del Carmen Ligero, María, Robau, Margarita, Miró, José María, Ocaña, Inmaculada, Burgos, Joaquín, Barberà, María José, Arando, Maider, Gutiérrez, F. lix, Masía, Mar, Blanco, José Ramón, Belda-Ibáñez, Josefina, García, Elisa Fernández, Espinosa, Trinidad Zafra, López-Lirola, Ana, Salavert, Miguel, Montero, Marta, Calabuig, Eva, Cuellar, Sandra, Vinciana, Pompeyo, Palacios, Reyes, García, Federico, Peña, Alejandro, Iribarren, José Antonio, Aguado, Mirian, Pulido, Federico, Portillo, Ángel, Gómez-Sirvent, José Luis, AII - Infectious diseases, Infectious diseases, and APH - Global Health

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Social stigma, Cross-sectional study, media_common.quotation_subject, Immigration, Stigma (botany), HIV Infections, Health Services Accessibility, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Epidemiology, Health care, Humans, Medicine, 030212 general & internal medicine, Young adult, Risk factor, media_common, Transients and Migrants, 030505 public health, business.industry, Public Health, Environmental and Occupational Health, Cross-Sectional Studies, Spain, Health Care Surveys, Female, 0305 other medical science, business, Demography
Abstract

Background In Spain, migrants are disproportionately affected by HIV and experience high rates of late diagnosis. We investigated barriers to health care access among migrants living with HIV (MLWH) in Spain. Methods Cross sectional electronic survey of 765 adult HIV-positive migrants recruited within 18 health care settings between July 2013 and July 2015. We collected epidemiological, demographic, behavioral and clinical data. We estimated the prevalence and risk factors of self-reported barriers to health care using multivariable logistic regression. Results Of those surveyed, 672 (88%) had information on health care access barriers: 23% were women, 63% from Latin America and Caribbean, 14% from Sub-Saharan Africa and 15% had an irregular immigration status. Men were more likely to report barriers than women (24% vs. 14%, P = 0.009). The main barriers were: lengthy waiting times for an appointment (9%) or in the clinic (7%) and lack of a health card (7%). Having an irregular immigration status was a risk factor for experiencing barriers for both men (OR: (4.0 [95%CI: 2.2-7.2]) and women (OR: 10.5 [95%CI: 3.1-34.8]). Men who experienced racial stigma (OR: 3.1 [95%CI: 1.9-5.1]) or food insecurity (OR: 2.1 [95%CI: 1.2-3.4]) were more likely to report barriers. Women who delayed treatment due to medication costs (6.3 [95%CI: 1.3-30.8]) or had a university degree (OR: 5.8 [95%CI: 1.3-25.1]) were more likely to report barriers. Conclusion Health care barriers were present in one in five5 MLWH, were more common in men and were associated to legal entitlement to access care, perceived stigma and financial constraints.

Published
2018
Full Text
View/download PDF

213. Discontinuation of primary and secondary toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial

Author

Miro, Jose M., Lopez, Juan C., Podzamczer, Daniel, Pena, Jose M., Alberdi, Juan C., Martinez, Esteban, Domingo, Pere, Cosin, Jaime, Claramonte, Xavier, Arribas, Jose R., Santin, Miguel, and Ribera, Esteban

Subjects
Toxoplasma -- Research, HIV patients -- Care and treatment, HIV patients -- Research, HIV patients -- Physiological aspects, Antiviral agents -- Usage, Clinical trials -- Management, Company business management, Health, Health care industry
Published
2006

214. Efficacy and safety of a once-daily fixed-dose combination of abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL3001 study)

Author

LaMarca, Anthony, Clumeck, Nathan, Plettenberg, Andreas, Domingo, Pere, Kaisong Fu, Craig, Charles, Zhao, Henry, Watson, Maria, Gordon, David, and Scott, Trevor

Subjects
Abacavir -- Dosage and administration, Abacavir -- Comparative analysis, Lamivudine -- Dosage and administration, Lamivudine -- Comparative analysis, HIV infection -- Drug therapy, Tenofovir -- Dosage and administration, Tenofovir -- Comparative analysis, Antiviral agents -- Dosage and administration, Antiviral agents -- Comparative analysis, Health
Abstract

A study to compare the efficacy and safety of the fixed-dose combination group to the separate entities group, in combination with tenofovir and a new protease inhibitor or nonnucleoside reverse transcription inhibitor in antiretroviral-experienced adults experiencing virologic failure is illustrated. Combination antiretroviral therapy has dramatically reduced the morbidity and mortality associated with HIV infection and a one-tablet, once-daily abacavir/lamivudine (FDC) has been recently approved to treat HIV-1 infection.

Published
2006

215. Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years

Author

Vidal, Francesc, Peraire, Joaquin, Fontanet, Angels, Domingo, Pere, Broch, Monteserrat, Dalmau, David, Cairo, Mireia, Pedrol, Enric, Deig, Elisabeth, Montero, Milagros, Vilades, Consuelo, Knobel, Hernando, Gutierrez, Cristina, Sambeat, M. Antonio, Sirvent, Joan Josep, and Richart, Cristobal

Subjects
HIV infection -- Genetic aspects, Single nucleotide polymorphisms -- Research, Chemokines -- Research, Health
Abstract

A cross-sectional genetic association case-control study is conducted to examine the association of the polymorphisms of the RANTES chemokine gene promoter with the long-term nonprogressive HIV-1 infection. The analysis suggests that the single nucleotide polymorphisms (Snips) in the RANTES associated with the long-term nonprogressors (LNTPs) cannot exceed more than sixteen years.

Published
2006

218. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

Author

Podzamczer, Daniel, primary, Micán, Rafael, additional, Tiraboschi, Juan, additional, Portilla, Joaquín, additional, Domingo, Pere, additional, Llibre, Josep Maria, additional, Ribera, Esteve, additional, Vivancos-Gallego, M.J., additional, Morano, L., additional, Masiá, Mar, additional, Gómez, Cristina, additional, Fanjul, Francisco, additional, Payeras, Antoni, additional, Inciarte, Alexy, additional, Estrada, Vicente, additional, Rivero, Antonio, additional, Castro, Ángeles, additional, Bernal, Enrique, additional, Vinuesa, David, additional, Knobel, Hernando, additional, Troya, Jesús, additional, Macías, Juan, additional, Montero, Marta, additional, Sanz, J., additional, Navarro-Alcaraz, Antonio, additional, Caicedo, Ana, additional, Fernández, Guillermo, additional, Martínez, Esteban, additional, and Moreno, Santiago, additional

Published
2021
Full Text
View/download PDF

219. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele

Author

Vidal, Francesc, Vilades, Consuedo, Domingo, Pere, Broch, Montserrat, Pedrol, Enric, Dalmau, David, Knobel, Hernando, Peraire, Joaquim, Gutierrez, Cristina, Sambeat, Antonia, Fontanet, Angels, Dieg, Elisabeth, Cairo, Mireia, Montero, Milagros, Richart, Cristobal, and Mallal, Simon

Subjects
Allelomorphism -- Research, Genetic variation -- Research, HIV infection -- Research, Genetic research, Health
Abstract

A study was conducted to determine whether functionally active CX3CR1 genetic variants are associated with long-term nonprogressive (LTNP) infection of less than 15 years in HIV-1 infected Spanish patients. The result shows that CX3CR1 249I variant allele is more frequent in Spanish HIV-1 infected LTNPs of less than 15 years, and the effect is independent of the presence of the CCR5(delta)32 allele.

Published
2005

220. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity

Author

Villarroya, Francesc, Domingo, Pere, and Giralt, Marta

Subjects
HIV (Viruses) -- Drug therapy, Highly active antiretroviral therapy -- Complications and side effects, Anti-HIV agents -- Complications and side effects, Antiviral agents -- Complications and side effects, Biological sciences, Chemistry, Pharmaceuticals and cosmetics industries
Abstract

The lipodystrophy syndrome and associated metabolic alterations are the most prevalent adverse effects in HIV-infected patients taking highly active anti-retroviral therapy (HAART). This syndrome involves profound disturbances in adipose tissue. The toxic effect of nucleoside reverse transcriptase inhibitors on mitochondrial function is a major contributor to the lipodystrophy syndrome. Although adipocytes were not expected to be preferential targets of mitochondrial toxicity, recent re-evaluation of the role of mitochondria in white adipocytes helps to explain the molecular basis of HAART-associated lipodystrophy. Adipocytes are a source of paracrine and endocrine signals that influence adipocyte biology and systemic metabolism. Mitochondrial disturbances elicited by HAART result in an abnormal perception of the bioenergetic status by adipocytes, thus leading to enhancement of catalytic pathways and apoptosis in peripheral adipose tissue, alterations in the differentiation of brown versus white adipocytes, and the release of hormonal signals that lead to systemic metabolic disturbances.

Published
2005

221. Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study

Author

Biglia, Alejandra, Blanco, Jose L., Martinez, Esteban, Domingo, Pere, Casamitjana, Roser, Sambeat, Maria, Milinkovic, Ana, Garcia, Mercedes, Laguno, Montserrat, Leon, Agathe, Larrousse, Maria, Lonca, Montserrat, Mallolas, Josep, and Gatell, Jose M.

Subjects
Hypogonadism -- Risk factors, Hypogonadism -- Research, Gynecomastia -- Risk factors, Gynecomastia -- Research, Health, Health care industry
Published
2004

222. Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 study

Author

Knobel, Hernando, Miro, Jose M., Mahillo, Beatriz, Domingo, Pere, Rivero, Antonia, Ribera, Esteban, Gonzalez, Juan, Gonzalez, Alicia, Blanco, Jose Luis, Boix, Vicente, Force, Luis, Llibre, Josep M., Dalmau, David, Arroyo, Juan A., Torre, Julian De la, Rodriguez, Dolors, Montes, Maria Luisa, Arranz, Alberto, Sarasa, Maria, and Jose, Sanz

Subjects
Cetirizine -- Dosage and administration, Nevirapine -- Diagnosis, Nevirapine -- Risk factors, Experimental design -- Research, Health
Abstract

An attempt was made to evaluate the efficacy of cetirizine in the prevention of nevirapine rash using a double-blind placebo-controlled study. By performing this study, it was concluded that cetirizine does not prevent the incidence or affect the severity of neviropine-associated rash.

Published
2004

223. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

Author

Martinez, Esteban, Domingo, Pere, Galindo, Maria J., Milinkovic, Ana, Arroyo, Juan A., Baldovi, Francisco, Larrousse, Maria, Leon, Agathe, de Lazzari, Elisa, and Gatell, Jose M.

Subjects
Ritonavir -- Health aspects, Hyperlipidemia -- Care and treatment, HIV infection -- Care and treatment, HIV infection -- Research, Blood sugar monitoring -- Research, Antiviral agents -- Health aspects, Antiviral agents -- Research, Health, Health care industry
Published
2004

224. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

Author

Mussini, Cristina, Pezzotti, Patrizio, Miro, Jose M., Martinez, Esteban, de Quiros, Juan Carlos Lopez Bernaldo, Cinque, Paola, Borghi, Vanni, Bedini, Andrea, Domingo, Pere, Cahn, Pedro, Bossi, Philippe, De Luca, Andrea, Monforte, Antonella d'Arminio, Nelson, Mark, Nwokolo, Nneka, Helou, Silvia, Negroni, Ricardo, Jacchetti, Gaia, Antinori, Spinello, Lazzarin, Adriano, Cossarizza, Andrea, Esposito, Roberto, Antinori, Andrea, and Aberg, Judith A.

Subjects
Health, Health care industry
Published
2004

227. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

Author

Martinez, Esteban, Arnaiz, Juan A., Podzamczer, Daniel, Dalmau, David, Ribera, Esteban, Domingo, Pere, Knobel, Hernando, Riera, Melcior, Pedrol, Enric, Force, Lluis, Llibre, Josep M., Segura, Ferran, Richart, Cristobal, Cortes, Cristina, Javaloyas, Manuel, Aranda, Miquel, Cruceta, Ana, Lazzari, Elisa de, and Gatell, Jose M.

Subjects
Abacavir -- Evaluation, HIV infection -- Drug therapy, Nevirapine -- Evaluation
Abstract

Nevirapine and efavirenz may be more effective AIDS drugs than abacavir, according to a study of 460 HIV patients. These drugs are often used instead of protease inhibitors because protease inhibitors have serious side effects. In this study, abacavir seemed to have fewer side effects than the other two drugs.

Published
2003

228. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. (Major Article: HIV/AIDS)

Author

Berenguer, Juan, Miralles, Pilar, Arrizabalaga, Julio, Ribera, Esteban, Dronda, Fernando, Baraia-Etxaburu, Josu, Domingo, Pere, Marquez, Manuel, Rodriguez-Arrond, Francisco J., Laguna, Fernando, Rubio, Rafael, Rodrigo, Jose Lacruz, Mallolas, J., and Miguel, Veronica de

Subjects
Communicable diseases -- Research, Leukoencephalopathy, Progressive multifocal -- Physiological aspects, Leukoencephalopathy, Progressive multifocal -- Patient outcomes, Highly active antiretroviral therapy -- Physiological aspects, Highly active antiretroviral therapy -- Research, AIDS (Disease) -- Physiological aspects, AIDS (Disease) -- Drug therapy, AIDS (Disease) -- Patient outcomes, Health, Health care industry
Published
2003

230. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: Report of 12 cases and review of the literature. (HIV/AIDS)

Author

Falco, Vicente, Rodriguez, Dolors, Ribera, Esteban, Martinez, Esteban, Miro, Jose Maria, Domingo, Pere, Diazaraque, Ruth, Arribas, Jose R., Gonzalez-Garcia, Juan J., Montero, Francesc, Sanchez, Lluis, and Pahissa, Albert

Subjects
Lactic acidosis -- Care and treatment, HIV infection -- Complications, Anti-HIV agents -- Adverse and side effects, Health, Health care industry
Published
2002

231. Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006–08)

Author

Romero, Anabel, González, Victoria, Esteve, Anna, Martró, Elisa, Matas, Lurdes, Tural, Cristina, Pumarola, Tomàs, Casanova, Aurora, Ferrer, Elena, Caballero, Estrella, Ribera, Esteve, Margall, Núria, Domingo, Pere, Farré, Joan, Puig, Teresa, Sauca, MGoretti, Barrufet, Pilar, Amengual, MJosé, Navarro, Gemma, Navarro, Maria, Vilaró, Josep, Ortín, Xavier, Ortí, Amat, Pujol, Ferran, Prat, Josep M., Massabeu, Àngels, Simó, Josep M., Villaverde, Carlos Alonso, Benítez, Miguel Ángel, Garcia, Isabel, Díaz, Olga, Becerra, Jasmina, Ros, Rosa, Sala, Roser, Rodrigo, Isabel, Miró, José M., and Casabona, Jordi

Published
2012
Full Text
View/download PDF

239. Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

Author

Macías, Juan, Neukam, Karin, Mallolas, Josep, López-Cortés, Luis F., Cartón, José A., Domingo, Pere, Moreno, Santiago, Iribarren, José A., Clotet, Bonaventura, Crespo, Manell, de Los Santos, Ignacio, Ortega, Enrique, Knobel, Hernando, Jiménez-Expósito, María J., and Pineda, Juan A.

Published
2012

241. Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study§

Author

Podzamczer, Daniel, Martínez, Esteban, Domingo, Pere, Ferrer, Elena, Viciana, Pompeyo, Curto, Jordi, Pérez-Elías, Maria-Jesús, Ocampo, Antonio, Santos, Ignacio, Knobel, Hernando, Estrada, Vicente, Negredo, Eugenia, Segura, Ferrán, Portilla, Joaquín, Ribera, Esteban, Galindo, Josefa, Antela, Antonio, Carmena, Jorge, and Castaño, Manuel

Published
2012

242. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/00 study

Author

Knobel, Hernando, Miro, Jose M., Domingo, Pere, Rivero, Antonio, Marquez, Manuel, Force, Luis, Gonzalez, Alicia, Miguel, Veronica de, Sanz, Jose, Boix, Vicente, Blanco, Jose Luis, and Locutura, Jaime

Subjects
Epidemiology -- Statistics, Epidemiology -- Research, HIV patients -- Case studies, HIV patients -- Health aspects, HIV patients -- Care and treatment, HIV infection -- Prevention, HIV infection -- Research, HIV infection -- Health aspects, Rash (Dermatology) -- Causes of, Placebos -- Physiological aspects, Clinical trials -- Analysis, Nevirapine -- Adverse and side effects, Nevirapine -- Physiological aspects, Prednisone -- Physiological aspects, Health
Abstract

Research has been conducted on side effects associated with nevirapine. The efficacy of prednisone in nevirapine-induced rash prevention has been investigated via the use of double-blind placebo and the results demonstrate that prednisone administration does not prevent nevirapine rash but increases its incidence.

Published
2001

243. Antiretroviral treatment simplification witih nevirapine in protease-inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study

Author

Ruiz, Lidia, Negredo, Eugenia, Domingo, Pere, Paredes, Roger, Francia, Esther, Balague, Montserrat, Gel, Silvia, Bonjoch, Anna, Fumaz, Carmina R., Johnston, Susan, Romeu, Joan, Lange, Joep, and Clotet, Bonaventura

Subjects
Lipid metabolism disorders -- Prognosis, HIV infection -- Drug therapy, Nevirapine -- Evaluation, Health
Abstract

Switching AIDS therapy from a combination of drugs that includes a protease inhibitor to one that includes nevirapine may benefit HIV patients with fat metabolism disorders caused by protease inhibitors. In a study of 106 HIV patients who switched, cholesterol levels decreased, but changes in body composition remained the same.

Published
2001

244. A randomized trial of hte discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

Author

Lopez Bernaldo de Quiros, Juan C., Miro, Jose M., Pena, Jose M., Podzamczer, Daniel, Alberdi, Juan C., Martinez, Esteban, Cosin, Jaime, Claramonte, Xavier, Gonzalez, Juan, Domingo, Pere, Casado, Jose L., and Ribera, Esteban

Subjects
HIV infection -- Drug therapy, Pneumocystis carinii pneumonia -- Prevention
Abstract

HIV patients whose CD4 T cell counts increase to 200 or more as a result of antiretroviral therapy can stop taking drugs to prevent Pneumocystis carinii pneumonia (PCP). In a study of 714 such patients, none of the 300 patients who stopped taking drugs to prevent PCP developed PCP during a one- to two-year follow-up.

Published
2001

248. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Author

Imaz, Arkaitz, Llibre, Josep M., Mora, Marta, Mateo, Gracia, Camacho, Angela, Blanco, José R., Curran, Adrian, Santos, José R., Caballero, Estrella, Bravo, Isabel, Gayá, Francisco, Domingo, Pere, Rivero, Antonio, Falcó, Vicenç, Clotet, Bonaventura, and Ribera, Esteban

Published
2011
Full Text
View/download PDF

250. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV–1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)

Author

Imaz, Arkaitz, primary, Tiraboschi, Juan M, additional, Niubó, Jordi, additional, Martinez-Picado, Javier, additional, Cottrell, Mackenzie L, additional, Domingo, Pere, additional, Chivite, Ivan, additional, Negredo, Eugenia, additional, Schauer, Amanda, additional, Van Horne, Brian, additional, Morenilla, Sandra, additional, Urrea, Víctor, additional, Silva-Klug, Ana, additional, Scévola, Sofía, additional, Garcia, Benito, additional, Kashuba, Angela D M, additional, and Podzamczer, Daniel, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results